Development of an Orally Delivered Genital Herpes Vaccine: Targeting the Reproductive Tract using Liporale, A Novel Lipid-based Adjuvant

Project dates: 2011-12-01 00:00:00 - 2014-12-31 00:00:00

This project will evaluate the potential of a novel lipid-based adjuvant platform, LiporaleTM, to induce protection against a model sexually transmitted infection, genital herpes, using an orally delivered vaccination approach. Currently 16 per cent of the world's population has been exposed to herpes and there is currently no effective vaccine available.

Funding / Grants

  • Australian Research Council



  • ARC Linkage - APAI or APDI - Immune Solutions Ltd

Professor Ken Beagley reproductive immunologist